Aryl receptor modulators and methods of making and using the same
US-12012418-B2 · Jun 18, 2024 · US
US12577256B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12577256-B2 |
| Application number | US-202418656965-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 7, 2024 |
| Priority date | Jun 27, 2014 |
| Publication date | Mar 17, 2026 |
| Grant date | Mar 17, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-7 in a subject.
Opening claim text (preview).
What is claimed is: 1 . A compound represented by: or a pharmaceutically acceptable salt thereof. 2 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 3 . A method of treating or reducing fibrostenosis or intestinal fibrosis in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof. 4 . A compound represented by: or a pharmaceutically acceptable salt thereof. 5 . A pharmaceutical composition comprising a compound according to claim 4 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 6 . A method of treating or reducing fibrostenosis or intestinal fibrosis in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 4 , or a pharmaceutically acceptable salt thereof.
Nitrogen atoms · CPC title
Nitrogen atoms · CPC title
with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 · CPC title
Nitrogen atoms not forming part of a nitro radical · CPC title
Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.